Physician profile
Karin Black
NPI 1366753584
$3,217.68
in general payments reported to CMS, 2019-2025
39 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $164 · 2021: $717 · 2022: $813 · 2023: $608 · 2024: $57.72 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.90 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $325.50 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $287.43 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $226.49 | 2019-2023 | Seglentis, Livalo |
| Novo Nordisk INC | $174.29 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $143.88 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $139.23 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $137.30 | 2021-2023 | Rexulti |
| Glaxosmithkline, LLC. | $116.14 | 2019-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Amgen INC. | $108.40 | 2019-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.90 | 2020-2025 | Ofev, Jardiance |
| Organogenesis INC. | $92.52 | 2019 | |
| Lilly USA, LLC | $89.43 | 2021-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $75.96 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.38 | 2025 | Caplyta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.